[go: up one dir, main page]

WO1999051279A1 - Procede de traitement de produits et articles contamines - Google Patents

Procede de traitement de produits et articles contamines Download PDF

Info

Publication number
WO1999051279A1
WO1999051279A1 PCT/AU1999/000249 AU9900249W WO9951279A1 WO 1999051279 A1 WO1999051279 A1 WO 1999051279A1 AU 9900249 W AU9900249 W AU 9900249W WO 9951279 A1 WO9951279 A1 WO 9951279A1
Authority
WO
WIPO (PCT)
Prior art keywords
denaturing agent
article
proteins
dna
gelatine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU1999/000249
Other languages
English (en)
Inventor
Hans Klieber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOKUTA Pty Ltd
Original Assignee
NOKUTA Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOKUTA Pty Ltd filed Critical NOKUTA Pty Ltd
Priority to JP2000542049A priority Critical patent/JP2002510657A/ja
Priority to NZ507037A priority patent/NZ507037A/en
Priority to AU31305/99A priority patent/AU746247B2/en
Priority to EP99913002A priority patent/EP1066062A4/fr
Publication of WO1999051279A1 publication Critical patent/WO1999051279A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/06—Gelatine
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09H—PREPARATION OF GLUE OR GELATINE
    • C09H3/00—Isolation of glue or gelatine from raw materials, e.g. by extracting, by heating
    • C09H3/02—Purification of solutions of gelatine

Definitions

  • the present invention relates to a method for treating products and articles contaminated or potentially contaminated with contagious pathogenic agents.
  • surfaces of articles, such as surgical apparatus, which come into contact with a contagious pathogenic agent may be the source of infection to other animals/humans if they are not suitably decontaminated and sterilised.
  • CJD Creutzfeldt-Jakob disease
  • BSE Bovine Spongiform Encephalopathy
  • the temperatures routinely used to sterilise surgical instruments in hospitals may help to spread CJD. Further, increasing the temperatures of the autoclave used to disinfect instruments may actually make it harder to destroy the CJD prions.
  • Pathogens are disease causing parasites which include DNA and/or proteins in their structural make-up. They cause disease by invading and multiplying in the living tissue of a host cell. Contagious pathogenic agents such as very small viruses, plasmids or prions have been known to cause brain diseases such as. "Mad Cow” disease (BSE), Creutzfeldt-Jacob disease (CJD) or Scrapie. Prions have been defined as proteins which have become sticky clumps and cause neurological havoc and are thought to be the cause of the brain diseases. Recent research postulates that prions may play a role in reproduction complimentary or additional to genes.
  • Native globular proteins and solutions of double helical DNA undergo significant changes in a number of physical properties when subjected to: heat; extremes of pH; exposure to strong solutions of amides such as urea or urea derivatives such as guanidine hydrochloride; organic solvents; radiation; enzymes; and detergents. This physical change is called denaturation. Denaturation of proteins and DNA yields unfolded, random conformations of their corresponding polypeptide and DNA chains and results in the loss of the proteins biological activity.
  • bonds which are affected by the denaturation process include hydrogen bonds; hydrophobic bonds; salt bridges or ionic bonds between groups which are positively and negatively charged; and intramolecular bonds such as are found in cross linkages due to the disulfide bond groups of cystine.
  • Urea and guanidine are examples of denaturation agents. Although the mechanism of action of these denaturing agents is not fully understood, it is believed that they disrupt non-covalent interactions.
  • polypeptide chains devoid of cross-links usually assume a random-coil confirmation in 8 M urea or 6 molar guanidine hydrochloride, as evidenced by physical properties such as viscosity and optical rotary spectra. These compounds break hydrogen bonds in the protein, presumably by forming hydrogen bonds of its own due to its peptide like character.
  • Disulfides bonds can be cleaved reversibly by reduction with a reagent such as beta-mercaptoethanol.
  • a reagent such as beta-mercaptoethanol.
  • the protein ribomiclease cannot be readily reduced by beta-mercaptoethanol unless the protein is partially unfolded by denaturing agents such as urea or guanidine hydrochloride.
  • the contagious pathogenic agents causing brain diseases such as "Mad Cow” disease, Creutzfeldt-Jacob disease or Scrapie are not destroyed by commonly used methods such as heat or radiation treatment.
  • the present inventor has surprisingly found that this can be achieved by treating the animal derived product or the surface of an article with denaturing agents such as urea derivatives.
  • the present invention relates to a method for the denaturation of proteins and/or DNA present in gelatine or other polypeptide products derived from animals, comprising treating the gelatine or other polypeptide product with a denaturing agent in an amount effective to denature the proteins and/or DNA without substantially affecting the gelatine or other polypeptide product.
  • the present invention relates to a method of treating gelatine or other polypeptide products derived from animals potentially contaminated with contagious pathogenic agents, comprising treating the gelatine or other polypeptide products with a denaturing agent in an amount effective to denature proteins and/or DNA of the contagious pathogenic agent without substantially affecting the gelatine or other polypeptide products.
  • the present invention relates to use of a denaturing agent for the denaturation of proteins and/or DNA present in gelatine or other polypeptide products derived from animals, wherein the gelatine or other polypeptide product is treated with the denaturing agent in an amount effective to denature the proteins and/or DNA without substantially affecting the gelatine or other polypeptide product.
  • the present invention is directed to the use of a denaturing agent for treating gelatine or other polypeptide products derived from animals potentially contaminated with contagious pathogenic agents. wherein the gelatine or other polypeptide products are treated with a denaturing agent in an amount effective to denature proteins and/or DNA of the contagious pathogenic agent without substantially affecting the gelatine or other polypeptide products.
  • the present invention relates to a denaturing agent when used to denature proteins and/or DNA present in gelatine or other polypeptide products derived from animals, wherein the gelatine or other polypeptide product is treated with the denaturing agent in an amount effective to denature the proteins and/or DNA without substantially affecting the gelatine or other polypeptide product.
  • the other polypeptide products derived from animals may be animal extracts or meat for animal or human consumption.
  • the present invention relates to a method for the denaturation of proteins and/or DNA present on the surface of an article, comprising treating the surface of the article with a denaturing agent in an amount effective to denature the proteins and/or DNA of the contagious pathogenic agent without substantially affecting the surface of the article.
  • the present invention relates to a method of treating a surface of an article potentially contaminated with contagious pathogenic agents, comprising treating the surface of the article with a denaturing agent in an amount effective to denature proteins and/or DNA of the contagious pathogenic agent without substantially affecting the surface of the article.
  • the present invention relates to use of a denaturing agent for the denaturation of proteins and/or DNA present on the surface of an article, wherein the surface of the article is treated with the denaturing agent in an amount effective to denature the proteins and/or DNA without substantially affecting the surface of the article.
  • the present invention is directed to the use of a denaturing agent for treating a surface of an article potentially contaminated with contagious pathogenic agents, wherein the surface of the article is treated with a denaturing agent in an amount effective to denature proteins and/or DNA of the contagious pathogenic agent without substantially affecting the surface of the article.
  • the present invention relates to a denaturing agent when used to denature proteins and/or DNA present on the surface of an article, wherein the surface of the article is treated with the denaturing agent in an amount effective to denature the proteins and/or DNA without substantially affecting the surface of the article.
  • the surface of the article to be treated may be soft or hard.
  • Soft surfaces includes surfaces which are malleable and have little or no resistance to pressure or weight and includes natural and synthetic fabrics.
  • Hard surfaces include surfaces which are firm or rigid and include steel and steel alloys such as stainless steel.
  • the surface of the article to be treated is the stainless steel surface of a surgical apparatus.
  • the proteins and/or DNA to be denatured are contained in or derived from contagious pathogenic agents.
  • the contagious pathogenic agents may be very small viruses, plasmids or prions.
  • the properties of the animal derived products or the surface of the article which are contaminated with the contagious pathogenic agent are not substantially affected when treated with the denaturing agent, such that the denaturing agent reacts with the proteins and/or DNA of the contagious pathogen rather than the animal product or the surface of the article.
  • Varying factors such as the concentration of the denaturing agent and the time of reaction between the denaturing agent and the contaminated animal product or surface of article may be used to control the reaction between the denaturing agent and the animal derived product and surface of the article.
  • the denaturing agent is the urea analogue compound according to formula (I):
  • X is selected from nitrogen or oxygen
  • the salt derivative of Formula (I) is preferably selected from the chloride, nitrate or aluminium sulphate salt.
  • the denaturing agent is non-toxic and selected from the group consisting of urea, guanidine, L(+)-Arginine, creatine and creatinine or salts thereof. More preferably, the urea derivative is guanidine or guanidine hydrochloride.
  • the animal derived product or surface of the article contaminated (or possibly contaminated) with the contagious pathogenic agent is treated with a 0.1% w/v up to a saturated solution, preferably a 5 to 10% w/v solution, of the denaturing agent.
  • the solution may be based on organic or non-organic solvents which dissolve the denaturing agent.
  • the solvent is selected from an alcohol, such as ethanol, water or an aqueous alcoholic mix.
  • the animal derived product contaminated with a contagious pathogenic agent may be treated in a dry state, as a gel or in a liquid, such as water, which is preferably heated to a temperature of over 40°C.
  • a dry animal derived product or surface of the article contaminated with a contagious pathogenic agent is washed with an alcoholic solution of the denaturing agent such that the denaturing agent does not dissolve the animal derived product or the surface of the article but allows reaction of the guanidine with the contagious pathogenic agent.
  • the contagious pathogen may be in the form of CJD prions or BSE prions.
  • the denaturing agent is guanidine or its hydrochloride salt and the solvent is ethanol, water or a water-ethanol mix.
  • the solvent may be removed by usual methods such as reduced pressure evaporation or drying at approximately 50°C to 80°C.
  • the remaining animal derived product and the residual denaturing agent may be treated in any one of the following manners:
  • the gelatine may be further purified by extraction into water, washing with ethanol and drying:
  • the denaturing agent provided it is non-toxic, can be left in the animal derived product (guanidine and its salts, for example, are generally non-toxic);
  • the amount of denaturing agent contaminating the animal derived product can be reduced by drying the gelatine and further purifying it by usual methods such as centrifugation, spray drying, adsorption etc:
  • a solution of the animal derived product or dry gelatine still containing a denaturing agent such as guanidine and or its salts can be treated in an autoclave type container with heat under pressure (equivalent to 160°C at normal pressure) to convert guanidine into ammonia (which evaporates or can be evaporated) and melamine.
  • the melamine which is almost insoluble in water can be separated (eg by filtration or centrifugation), from a solution of the animal derived product in a non-organic solvent.
  • the treated animal derived product can be further purified by usual processes, such as extraction into water, washing with ethanol and drying.
  • the surface of articles contaminated or potentially contaminated with BSE prions may be treated by immersing the article in a 0.1% w/v up to a saturated solution, preferably a 5 to 10% w/v solution, of the denaturing agent in a solvent such as an aqueous or alcoholic solution.
  • a solvent such as an aqueous or alcoholic solution.
  • the article is immersed in 5 to 10% w/v guanidine or guanidine hydrochloride in either ethanol or water for one hour at approximately 40-50°C or in an autoclave for 10-20 minutes at 130-140°C. Any other sterilising processes can be additionally applied in the conventional manner.
  • the denaturing process renders the pathogen harmless.
  • the denaturing agent and the solvent may be removed by separating the treated material from the solution.
  • the treated material may then be washed with pure solvent such as water or alcohol followed by drying.
  • the utilised denaturing agent is guanidine or its salts and a method such as autoclaving has been used which brings the conditions to an equivalent of 160°C or more the guanidine is converted to melamine and ammonia. Both can be easily separated from the treated material by washing or a similar process. The denatured and rendered harmless pathogen no longer needs to be separated from the treated material.
  • Example 1 Treatment of Gelatine Gelatine is water soluble at > 40°C and is a mix of proteins derived by partial hydrolysis of animal collagen. According to the invention, gelatine contaminated with a contagious pathogenic agent, such as BSE prions, may be treated according to any one of the following methods:
  • a 10 micron to 200 micron layer of gelatine contaminated with BSE prions may be treated with 10% w/v guanidine hydrochloride in water.
  • the solvent from the mixture may then be removed under reduced pressure evaporation to leave the decontaminated gelatine and residual guanidine hydrochloride.
  • the gelatine may be further purified by extraction into water, washing with ethanol and drying.
  • a 300 micron to 1 mm layer of gelatine contaminated with BSE prions may be treated with 5% w/v guanidine in ethanol.
  • the solvent from the mixture may be removed by reduced pressure evaporation.
  • the gelatine residue may be further purified by extraction into water, washing with ethanol and drying.
  • the gelatine may be further purified by centrifugation to reduce the contamination by guanidine.
  • a solution of 20% w/v gelatine in water at > 40°C may be treated with 10% w/v guanidine hydrochloride in water.
  • the solvent from the mixture may be removed by reduced pressure evaporation or drying at 50°C to 80°C.
  • guanidine hydrochloride may be eliminated from the gelatine by utilising the different solubilities of the two substances.
  • the resulting gelatine residue may be further purified by washing with ethanol and drying; or
  • a gel of 30% w/v gelatine in water at room temperature may be treated with 15% w/v guanidine hydrochloride in water.
  • the gelatine solution or the dry gelatine still containing guanidine hydrochloride may be treated in an autoclave type container with heat under pressure (equivalent to 160°C at normal pressure) to convert guanidine into ammonia and melamine.
  • the ammonia may be evaporated.
  • the melamine may be separated by filtration from a solution of gelatine in a non-organic solvent.
  • the resulting gelatine residue may be further purified by washing with ethanol and drying.
  • Example 2 Treatment of other animal derived article
  • the treatment of other material (besides gelatine) derived from animal material contaminated with a contagious pathogenic agent, such as, animal extracts or meat can be carried out according to any one of methods 1 to 4 outlined in Example 1 although the chosen method may depend on the different solubilities and adsorption characteristics of the material to be treated.
  • Example 3 Treatment of surface of surgical instruments:
  • surfaces of articles contaminated with a contagious pathogenic agent such as BSE or CJD prions, may be treated according to either one of the following methods: 10
  • the surgical instruments were removed and rinsed in water. Additionally, in (2), the instruments may be further sterilised in the conventional manner, such as. in an autoclave.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de dénaturation de protéines et/ou d'ADN, présents dans des produits dérivés d'animaux, ou sur la surface d'un article, ce procédé consistant à traiter le produit dérivé, ou la surface de l'article, à l'aide d'un agent de dénaturation dosé efficacement pour dénaturer la protéine et/ou l'ADN.
PCT/AU1999/000249 1998-04-01 1999-04-01 Procede de traitement de produits et articles contamines Ceased WO1999051279A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000542049A JP2002510657A (ja) 1998-04-01 1999-04-01 汚染された生産物及び物品を処理する方法
NZ507037A NZ507037A (en) 1998-04-01 1999-04-01 A method for treating products and articles contaminated with contagious pathogens by treatment with a urea analogue
AU31305/99A AU746247B2 (en) 1998-04-01 1999-04-01 A method for treating contaminated products and articles
EP99913002A EP1066062A4 (fr) 1998-04-01 1999-04-01 Procede de traitement de produits et articles contamines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP2760 1998-04-01
AUPP2760A AUPP276098A0 (en) 1998-04-01 1998-04-01 A method for treating gelatine

Publications (1)

Publication Number Publication Date
WO1999051279A1 true WO1999051279A1 (fr) 1999-10-14

Family

ID=3807021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1999/000249 Ceased WO1999051279A1 (fr) 1998-04-01 1999-04-01 Procede de traitement de produits et articles contamines

Country Status (5)

Country Link
EP (1) EP1066062A4 (fr)
JP (1) JP2002510657A (fr)
AU (1) AUPP276098A0 (fr)
NZ (1) NZ507037A (fr)
WO (1) WO1999051279A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062400A1 (fr) * 2001-02-07 2002-08-15 Novapharm Research (Australia) Pty Ltd Desinfection prionique
US8293174B2 (en) 2007-10-17 2012-10-23 American Sterilizer Company Prion deactivating composition and methods of using same
US8520843B2 (en) 2001-08-07 2013-08-27 Fraunhofer-Gesellscaft zur Foerderung der Angewandten Forschung E.V. Method and apparatus for encrypting a discrete signal, and method and apparatus for decrypting

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022151426A (ja) * 2021-03-26 2022-10-07 均 石井 上気道炎治療薬。
JP2022151438A (ja) * 2021-03-26 2022-10-07 均 石井 外耳炎と中耳炎と内耳炎の治療薬。

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374063A (en) * 1981-09-28 1983-02-15 General Foods Corporation Process for the preparation and purification of gelatin and pyrogen-free gelatin so prepared
AU5045390A (en) * 1989-01-31 1990-08-24 Paul L. Simmons Biodegradable disinfectant
WO1995009657A1 (fr) * 1993-10-06 1995-04-13 Immuno Aktiengesellschaft Procede permettant d'inactiver un virus en presence de polyalkyleneglycol et preparation pharmaceutique ainsi realisee
WO1995018529A1 (fr) * 1994-01-04 1995-07-13 Organogenesis, Inc. Sterilisation par l'acide peracetique
EP0742018A2 (fr) * 1995-05-01 1996-11-13 Collagen Corporation Inactivation de prions dans des matériaux à base de tissu conjonctif
EP0748632A1 (fr) * 1995-06-13 1996-12-18 BIOLAND Société à Responsabilité Limitée Procédé de traitement antiviral des tissus biologiques à trame collagénique
WO1997028192A1 (fr) * 1996-01-29 1997-08-07 Charles Doillon Collagene et produits derives exempts de prions, et implants pour applications biomedicales multiples; leurs procedes de fabrication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD141968A3 (de) * 1977-11-07 1980-06-04 Gottfried Schuster Mittel zur chemotherapie von kulturpflanzenvirosen
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
DE3720228A1 (de) * 1987-06-17 1988-12-29 Kreussler Chem Fab Verfahren und mittel zur desinfektion von chemischreinigungsmaschinen
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5300059A (en) * 1991-11-19 1994-04-05 Hydro Slip Technologies Inc. Bloodbag and method of making same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374063A (en) * 1981-09-28 1983-02-15 General Foods Corporation Process for the preparation and purification of gelatin and pyrogen-free gelatin so prepared
AU5045390A (en) * 1989-01-31 1990-08-24 Paul L. Simmons Biodegradable disinfectant
WO1995009657A1 (fr) * 1993-10-06 1995-04-13 Immuno Aktiengesellschaft Procede permettant d'inactiver un virus en presence de polyalkyleneglycol et preparation pharmaceutique ainsi realisee
WO1995018529A1 (fr) * 1994-01-04 1995-07-13 Organogenesis, Inc. Sterilisation par l'acide peracetique
EP0742018A2 (fr) * 1995-05-01 1996-11-13 Collagen Corporation Inactivation de prions dans des matériaux à base de tissu conjonctif
EP0748632A1 (fr) * 1995-06-13 1996-12-18 BIOLAND Société à Responsabilité Limitée Procédé de traitement antiviral des tissus biologiques à trame collagénique
WO1997028192A1 (fr) * 1996-01-29 1997-08-07 Charles Doillon Collagene et produits derives exempts de prions, et implants pour applications biomedicales multiples; leurs procedes de fabrication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1066062A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062400A1 (fr) * 2001-02-07 2002-08-15 Novapharm Research (Australia) Pty Ltd Desinfection prionique
KR100927494B1 (ko) * 2001-02-07 2009-11-17 노바팜 리서치(오스트레일리아)피티와이리미티드 프리온의 소독 방법
CN1494438B (zh) * 2001-02-07 2010-05-05 诺瓦制药研究(澳大利亚)股份有限公司 朊病毒的消毒
US9480761B2 (en) 2001-02-07 2016-11-01 Novapharm Research (Australia) Pty Ltd. Prion disinfection
US8520843B2 (en) 2001-08-07 2013-08-27 Fraunhofer-Gesellscaft zur Foerderung der Angewandten Forschung E.V. Method and apparatus for encrypting a discrete signal, and method and apparatus for decrypting
US8293174B2 (en) 2007-10-17 2012-10-23 American Sterilizer Company Prion deactivating composition and methods of using same

Also Published As

Publication number Publication date
JP2002510657A (ja) 2002-04-09
EP1066062A1 (fr) 2001-01-10
NZ507037A (en) 2002-03-01
EP1066062A4 (fr) 2002-10-16
AUPP276098A0 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
EP0742018B1 (fr) Inactivation de prions dans des matériaux à base de tissu conjonctif
EP0696617B1 (fr) Procédé pour contrôler la stabilité de structure des fibres de collagène préparées à partir de solutions ou dispersions traitées avec l'hydroxyde de sodium pour la désactivation d'agents infectieux
EP1856272B1 (fr) Procede de separation de collagene de tissu animal, procede de fabrication de solution de collagene et produit manufacture utilisant un tel procede
JP5505853B2 (ja) 微酸性アルギニンを添加剤とするウイルス不活化法
KR20000077321A (ko) 저취성 및 개선된 기계적 성질을 갖는 해산물 유래콜라겐을 함유한 콜라겐 제품, 화장용 또는 약학적 조성물또는 제품으로서의 그 용도
CA2243193A1 (fr) Collagene et produits derives exempts d'agents infectieux, les implants comprenants ces produits et leurs procedes de fabrication
CN111358731A (zh) 一种新型免洗消毒液及使用方法
WO1999051279A1 (fr) Procede de traitement de produits et articles contamines
AU2002227785B2 (en) Prion disinfection
AU746247B2 (en) A method for treating contaminated products and articles
AU2002227785A1 (en) Prion disinfection
JP2005343851A (ja) 魚類由来のペプチド及びその製造方法
US7922970B2 (en) Use of sonication to eliminate prions
RU2005141134A (ru) Водный раствор оланексидина, способ получения водного раствора и дезинфицирующее средство
US20040265785A1 (en) Method for treating materials of biological origin, and collagen-elastin product
RU2071788C1 (ru) Средство для лечения ран
JP5328077B2 (ja) 低エンドトキシン化ゼラチンの製造方法
JP2005289841A (ja) 無菌ゼラチンの製造方法
JPWO2001062305A1 (ja) プリオンを不活性化する方法およびそれに用いる処理溶液
WO2001062305A1 (fr) Procede d'inactivation du prion et solution de traitement a utiliser dans celui-ci
Dan et al. Study on some characteristics of fish scale collagen modified by UV irradiation
RU2113225C1 (ru) Способ получения молекулярно-растворимого кератина "кератана"
AU2005100872A4 (en) Prion disinfection
HK1088564A (en) Cleaning and decontamination formula for surfaces contaminated with prion-infected material
FR2557799A1 (fr) Emploi de l'acide abietique comme produit filmogene a utiliser sur les plaies et brulures.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 31305/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 507037

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999913002

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999913002

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWE Wipo information: entry into national phase

Ref document number: 09647665

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 31305/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999913002

Country of ref document: EP